DIABIO Stock Overview
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Diagonal Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.082 |
| 52 Week High | kr0.82 |
| 52 Week Low | kr0.068 |
| Beta | 0.66 |
| 1 Month Change | -5.23% |
| 3 Month Change | -69.81% |
| 1 Year Change | -82.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIABIO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -9.7% | -0.06% | 0.9% |
| 1Y | -82.9% | -5.3% | 10.3% |
Return vs Industry: DIABIO underperformed the Swedish Biotechs industry which returned -4.3% over the past year.
Return vs Market: DIABIO underperformed the Swedish Market which returned 10.7% over the past year.
Price Volatility
| DIABIO volatility | |
|---|---|
| DIABIO Average Weekly Movement | 37.6% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: DIABIO's share price has been volatile over the past 3 months.
Volatility Over Time: DIABIO's weekly volatility has increased from 29% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Karin Wehlin | diagonalbio.com |
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. It is involved in developing the Panviral platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria, and fungi. The company was incorporated in 2020 and is headquartered in Lund, Sweden.
Diagonal Bio AB (publ) Fundamentals Summary
| DIABIO fundamental statistics | |
|---|---|
| Market cap | kr3.26m |
| Earnings (TTM) | -kr11.68m |
| Revenue (TTM) | kr3.15m |
1.0x
P/S Ratio-0.3x
P/E RatioIs DIABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIABIO income statement (TTM) | |
|---|---|
| Revenue | kr3.15m |
| Cost of Revenue | kr18.00k |
| Gross Profit | kr3.13m |
| Other Expenses | kr14.81m |
| Earnings | -kr11.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 99.43% |
| Net Profit Margin | -370.61% |
| Debt/Equity Ratio | 0% |
How did DIABIO perform over the long term?
See historical performance and comparison